NAGE Key Statistics, Chart & Performance
The current stock price of NAGE is 6.77 USD. In the past month the price decreased by -4.78%.
NAGE Latest News, Press Relases and Analysis
NAGE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.38 | 221.98B | ||
| DHR | DANAHER CORP | 29.41 | 160.19B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 186.73 | 56.74B | ||
| A | AGILENT TECHNOLOGIES INC | 27.51 | 43.52B | ||
| IQV | IQVIA HOLDINGS INC | 19.78 | 39.17B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.29 | 30.17B | ||
| WAT | WATERS CORP | 31.77 | 24.02B | ||
| ILMN | ILLUMINA INC | 30.15 | 20.09B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.21 | 19.95B | ||
| MEDP | MEDPACE HOLDINGS INC | 41.43 | 16.69B | ||
| TEM | TEMPUS AI INC | N/A | 13.86B | ||
| RVTY | REVVITY INC | 21.8 | 11.84B |
Related stock screener links
About NAGE
Company Profile
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
Company Info
NIAGEN BIOSCIENCE INC
10900 Wilshire Blvd Suite 600
Los Angeles CALIFORNIA US
Employees: 104
Phone: 13103886706
NIAGEN BIOSCIENCE INC / NAGE FAQ
What does NAGE do?
Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 104 full-time employees. The company went IPO on 2007-06-25. The company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. The Company’s Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients directly to consumers and distributors and offers NAD+ test kits exclusively to healthcare practitioners. The Ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and United States FDA-registered 503B outsourcing facilities, respectively. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
What is the current price of NAGE stock?
The current stock price of NAGE is 6.77 USD. The price decreased by -1.74% in the last trading session.
Does NAGE stock pay dividends?
NAGE does not pay a dividend.
How is the ChartMill rating for NIAGEN BIOSCIENCE INC?
NAGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Which stock exchange lists NAGE stock?
NAGE stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of NAGE stock?
NIAGEN BIOSCIENCE INC (NAGE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is the next earnings date for NAGE stock?
NIAGEN BIOSCIENCE INC (NAGE) will report earnings on 2026-03-02, after the market close.
NAGE Technical Analysis
NAGE Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to NAGE. NAGE has an excellent financial health rating, but there are some minor concerns on its profitability.
NAGE Financial Highlights
Over the last trailing twelve months NAGE reported a non-GAAP Earnings per Share(EPS) of 0.24. The EPS increased by 2300% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.38% | ||
| ROA | 20.82% | ||
| ROE | 28.91% | ||
| Debt/Equity | 0 |
NAGE Forecast & Estimates
11 analysts have analysed NAGE and the average price target is 16.12 USD. This implies a price increase of 138.05% is expected in the next year compared to the current price of 6.77.
For the next year, analysts expect an EPS growth of 46.88% and a revenue growth 30.1% for NAGE